Ladiratuzumab  (Synonyms: hLIV22)

Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC)^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Ladiratuzumab ADC molecule, Ladiratuzumab vedotin (SGN-LIV1A), induces microtubule network disruption and inhibited cell growth in MCF-7 and BR0555 breast cancer cell line experiments, showing antigen-specific cytotoxicity^[1].
LIV-1 is a transmembrane protein and an estrogen-induced gene in breast cancer cells. Ladiratuzumab vedotin inhibits cell proliferation in LIV-1-positive breast cancer cells in vitro in a dose-dependent manner and has anti-tumor activity targeting LIV-1^[1][2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

146960.00

1629760-28-6

Liquid

Colorless to light yellow

[Ladiratuzumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized LIV-1/SLC39A6 Protein, Human (HEK293, His, HY-P78749) can bind Ladiratuzumab. The EC₅₀ for this effect is 8.853 ng/mL.

• [1]. Trail PA, et al. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018 Jan;181:126-142.  [Content Brief]

  [2]. Cao, et al. Additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor. Cancer Research 78.13_Supplement (2018): 2742-2742.